Results 181 to 190 of about 211,078 (328)

Providing holistic care for patients with metabolic dysfunction‐associated steatotic liver disease/metabolic dysfunction‐associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.
Lanlan Chen, Paul Horn, Frank Tacke
wiley   +1 more source

Winter‐active spiders (Clubiona) have a hyperactive antifreeze protein with a unique beta‐solenoid fold

The FEBS Journal, EarlyView.
Antifreeze proteins from winter‐active spiders were purified using their affinity for ice. After LC–MSMS characterization, corresponding transcripts were identified. The antifreeze protein folds as a β‐solenoid with a large flat ice‐binding site on one surface and can bind to ice crystals and prevent their growth at −4 °C.
Laurie A. Graham, Stano Pekár, Ina M. Hainer, Peter L. Davies   +3 more
wiley   +1 more source

Intratumoral PD-1^high CD8⁺ T cells correlate with AFP levels in HCC patients: a brief report. [PDF]

Cell Oncol (Dordr)
Macek Jilkova Z, Ghelfi J, Dumolard L, Sengel C, Brusset B, Teyssier Y, Costentin C, Decaens T.   +7 more
europepmc   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Secretory versus non-secretory hepatocellular carcinoma: associations of serum AFP, CEA and CA19-9 levels with clinical presentation, metastatic patterns, and survival. [PDF]

J Circ Biomark
Emmamally M, Kotze U, Khan R, Bernon M, Sobnach S, Krige JE, Spearman CW, Sonderup M, Jonas E.   +8 more
europepmc   +1 more source

\u27Despicable\u27 conditions at China iPhone plant [PDF]

, 2015
AFP, China Labor Watch
core   +1 more source

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Novel biomarkers for early detection of HCC in patients with MASLD or ALD. [PDF]

Hepatol Commun
Deodhar S, Jarrah M, Parikh ND, Al-Hasan M, Gopal P, Singal AG.   +5 more
europepmc   +1 more source

Efficacy and Safety of Second‐Line Lenvatinib After First‐Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma

Hepatology Research, EarlyView.
ABSTRACT Background There is a paucity of data regarding the efficacy and safety of lenvatinib as a second‐line treatment following first‐line combination immunotherapy with durvalumab and tremelimumab (Dur + Tre). Methods This retrospective multicenter study included 14 patients with unresectable hepatocellular carcinoma who received lenvatinib after ...
Ryoichi Miura, Tomokazu Kawaoka, Saki Sueda, Aiko Tanaka, Kou Hashimoto, Tomoaki Emori, Yasutoshi Fujii, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Shinsuke Uchikawa, Nami Mori, Keiji Tsuji, Yosuke Suehiro, Keiichi Masaki, Michihiro Nonaka, Kenji Yamaoka, Yoshio Katamura, C. Nelson Hayes, Masataka Tsuge, Shiro Oka   +21 more
wiley   +1 more source

Roles of AFP, AFP-L3, DCP and GP73 in Diagnosis of Hepatocellular Carcinoma and Prediction of Recurrence in Patients. [PDF]

J Cancer
Liao Y, Mo Z, Ye C, Chen Y, Dong H, Hu B.   +5 more
europepmc   +1 more source